Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurol Sci ; 364: 105-9, 2016 May 15.
Article in English | MEDLINE | ID: mdl-27084226

ABSTRACT

INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.


Subject(s)
Immunologic Factors/therapeutic use , Mood Disorders/etiology , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Treatment Outcome , Adolescent , Adult , Aged , Female , Humans , Italy , Logistic Models , Male , Middle Aged , Prospective Studies , Psychiatric Status Rating Scales , Psychometrics , Young Adult
2.
Eur J Dermatol ; 16(1): 72-4, 2006.
Article in English | MEDLINE | ID: mdl-16436347

ABSTRACT

We report the case of a 72-year-old woman with sporadic Creutzfeldt-Jakob's disease who presented a large purplish erythematous and edematous lesion, with subsequent bullous detachment on the anterior right thigh. The lesion rapidly evolved into an ulcer covered by a blackish necrotic eschar. Histological examination showed intense necrotizing leukocytoclastic vasculitis in the deep and middle dermis. Direct immunofluorescence revealed C3 and IgM deposits around vessels of the middle and deep dermis. The diagnosis of sporadic Creutzfeldt-Jacob's was confirmed post-mortem by immunoblotting on frozen brain tissue which showed pathologic proteinase-resistant prion-related protein isoform glycotype 2A. In the literature, only two cases of Creutzfeldt-Jakob's disease and cutaneous manifestations are reported.


Subject(s)
Creutzfeldt-Jakob Syndrome/diagnosis , Skin Diseases, Vascular/pathology , Aged , Autopsy , Biopsy, Needle , Creutzfeldt-Jakob Syndrome/complications , Disease Progression , Fatal Outcome , Female , Humans , Immunohistochemistry , Rare Diseases , Risk Assessment , Severity of Illness Index , Skin Diseases, Vascular/complications , Skin Diseases, Vascular/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...